Physician profile
Nader A Abdallah
NPI 1649519455
$153.92
in general payments reported to CMS, 2019-2025
7 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $43.44 · 2021: $95.20 · 2022: $15.28.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $36.29 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $24.63 | 2021 | |
| Pfizer INC. | $24.61 | 2020 | |
| Vivus LLC | $19.67 | 2021 | |
| Dermira, INC. | $18.83 | 2020 | |
| Dexcom, INC. | $15.40 | 2021 | |
| Horizon Therapeutics Plc | $14.49 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nader Abdallah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.